Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study (Q38459489)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 December 2012

Language	Label	Description	Also known as
English	Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study	scientific article published on 17 December 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Alexander Fosså

11

object named as

A Fosså

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

4

object named as

O Fluge

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Mikael Eriksson

19

object named as

M Eriksson

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Marie Nordström

14

object named as

M Nordström

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1

object named as

H Holte

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Henrik A Kolstad

10

object named as

A Kolstad

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

author name string

S Leppä

2

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

M Björkholm

3

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

S Jyrkkiö

5

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

C Sundström

7

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

M-L Karjalainen-Lindsberg

8

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

M Erlanson

9

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

B Ostenstad

12

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

E Löfvenberg

13

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

R Janes

15

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

L M Pedersen

16

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

H Anderson

17

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

M Jerkeman

18

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

publication date

17 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1385-1392

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Stromal gene signatures in large-B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS621

21 January 2018

Identifiers

10.1093/ANNONC/MDS621

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38459489&oldid=1760495755"